PL1675573T3 - Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób - Google Patents

Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób

Info

Publication number
PL1675573T3
PL1675573T3 PL04795514T PL04795514T PL1675573T3 PL 1675573 T3 PL1675573 T3 PL 1675573T3 PL 04795514 T PL04795514 T PL 04795514T PL 04795514 T PL04795514 T PL 04795514T PL 1675573 T3 PL1675573 T3 PL 1675573T3
Authority
PL
Poland
Prior art keywords
controlled release
sterile injectable
aripiprazole formulation
release sterile
injectable aripiprazole
Prior art date
Application number
PL04795514T
Other languages
English (en)
Other versions
PL1675573T5 (pl
PL1675573T4 (pl
Inventor
Janusz W Kostanski
Takakuni Corpo Faburesu B-201 MATSUDA
Manoj Nerurkar
Vijay H Naringrekar
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1675573(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PL1675573T3 publication Critical patent/PL1675573T3/pl
Publication of PL1675573T5 publication Critical patent/PL1675573T5/pl
Publication of PL1675573T4 publication Critical patent/PL1675573T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL04795514T 2003-10-23 2004-10-18 Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób PL1675573T4 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51361803P 2003-10-23 2003-10-23
EP04795514A EP1675573B2 (en) 2003-10-23 2004-10-18 Controlled release sterile injectable aripiprazole formulation and method
PCT/US2004/034367 WO2005041937A2 (en) 2003-10-23 2004-10-18 Controlled release sterile injectable aripiprazole formulation and method

Publications (3)

Publication Number Publication Date
PL1675573T3 true PL1675573T3 (pl) 2009-04-30
PL1675573T5 PL1675573T5 (pl) 2012-10-31
PL1675573T4 PL1675573T4 (pl) 2016-04-29

Family

ID=34549292

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04795514T PL1675573T4 (pl) 2003-10-23 2004-10-18 Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób

Country Status (32)

Country Link
US (12) US7807680B2 (pl)
EP (1) EP1675573B2 (pl)
JP (2) JP4836797B2 (pl)
KR (1) KR100931784B1 (pl)
CN (1) CN1870980B (pl)
AR (2) AR046141A1 (pl)
AT (1) ATE411797T2 (pl)
AU (1) AU2004285448C1 (pl)
BR (1) BRPI0415531B8 (pl)
CA (1) CA2543242C (pl)
CO (1) CO5690539A2 (pl)
CY (2) CY1109040T1 (pl)
DE (1) DE602004017342D1 (pl)
DK (1) DK1675573T4 (pl)
EC (2) ECSP066512A (pl)
ES (1) ES2315721T5 (pl)
FR (1) FR14C0039I1 (pl)
GE (1) GEP20115205B (pl)
IL (1) IL175072A (pl)
LU (1) LU92427I2 (pl)
MX (1) MXPA06004489A (pl)
MY (1) MY146093A (pl)
NO (2) NO334919B1 (pl)
NZ (1) NZ546063A (pl)
PE (1) PE20050811A1 (pl)
PL (1) PL1675573T4 (pl)
PT (1) PT1675573E (pl)
SI (1) SI1675573T2 (pl)
TW (2) TWI421101B (pl)
UA (1) UA82561C2 (pl)
WO (1) WO2005041937A2 (pl)
ZA (1) ZA200602347B (pl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
CN102627603A (zh) * 2004-11-18 2012-08-08 斯索恩有限公司 制备结晶阿立哌唑的方法
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
CN101351193A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的干法制剂
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
BRPI0813274A2 (pt) * 2007-06-25 2014-12-30 Otsuka Pharma Co Ltd Microesferas tendo estrutura de núcleo/revestimento
WO2009017250A1 (en) * 2007-07-31 2009-02-05 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN102218040A (zh) * 2010-04-13 2011-10-19 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
CN103025318B (zh) 2010-08-24 2016-07-06 大塚制药株式会社 含有喹啉酮衍生物、和硅油和/或硅油衍生物的悬浮液和块状组合物
KR101936968B1 (ko) 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
US9757374B2 (en) * 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
MX339196B (es) * 2010-10-28 2016-05-16 Aequus Pharmaceuticals Inc Composiciones de aripiprazol y metodos para su suministro transdermico.
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
CA2910333C (en) * 2011-01-24 2017-03-07 Otsuka Pharmaceutical Co., Ltd. Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
ES2604558T3 (es) 2011-03-18 2017-03-07 Alkermes Pharma Ireland Limited Composiciones farmacéuticas inyectables que comprenden un antipsicótico insoluble en agua, laurato de sorbitán y polisorbato 20
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102846543B (zh) * 2011-06-27 2014-11-19 上海中西制药有限公司 一种阿立哌唑药物制剂及其制备方法
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
EP2827866B1 (en) 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6450314B2 (ja) 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
EP2888277A4 (en) * 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PL2888284T3 (pl) 2012-08-21 2023-02-27 Janssen Pharmaceutica Nv Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
AU2013305887B2 (en) 2012-08-21 2018-02-22 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
HK1211956A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CA2910665C (en) * 2013-04-30 2018-05-22 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP6524110B2 (ja) 2014-03-20 2019-06-05 アルカームス ファーマ アイルランド リミテッド 注射速度が増大したアリピプラゾール調合物
RU2705376C2 (ru) 2014-08-18 2019-11-07 Алкермес Фарма Айэленд Лимитед Композиции пролекарства арипипразола
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
PT3185867T (pt) * 2014-08-25 2021-04-12 Alkermes Pharma Ireland Ltd Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
TWI584823B (zh) * 2015-08-31 2017-06-01 諾瑞特國際藥業股份有限公司 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
JP6504019B2 (ja) * 2015-10-27 2019-04-24 豊田合成株式会社 発光装置
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CN105663057A (zh) * 2015-12-30 2016-06-15 中国药科大学 阿立哌唑长效混悬剂及其制备方法
EP3490529A1 (en) * 2016-07-28 2019-06-05 Mylan Laboratories Ltd. Process for preparing sterile aripiprazole formulation
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN112545995B (zh) 2018-05-16 2024-02-23 珠海市丽珠微球科技有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
KR102486564B1 (ko) * 2019-08-23 2023-01-19 주식회사 대웅테라퓨틱스 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
WO2021140424A1 (en) * 2020-01-06 2021-07-15 Shilpa Medicare Limited Fingolimod extended release injectable suspension
US20230310417A1 (en) 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN115768407A (zh) * 2020-05-21 2023-03-07 江苏先声药业有限公司 一种含依匹哌唑药物组合物及其制备方法
KR102785446B1 (ko) * 2020-09-09 2025-03-25 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 항인플루엔자 바이러스용 조성물
CN112656761B (zh) * 2020-12-30 2023-09-08 河南合智医药科技有限公司 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
GR1010624B (el) * 2023-03-23 2024-01-30 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει αριπιπραζολη και μεθοδος για την παρασκευη αυτου
GR1010656B (el) * 2023-03-23 2024-03-21 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2024225441A1 (en) 2023-04-26 2024-10-31 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
US4038389A (en) 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JPH03212852A (ja) 1990-01-18 1991-09-18 Hitachi Electron Eng Co Ltd 記録媒体カートリッジ搬送装置における送り機構
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
EP0461930B1 (en) 1990-06-15 1995-09-13 Merck & Co. Inc. A crystallization method to improve crystal structure and size
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
SK282231B6 (sk) 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
DE69530196T2 (de) 1994-06-02 2003-11-20 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ATE252891T1 (de) 1996-08-26 2003-11-15 Transgene Sa Kationische lipid-nukleinsäure komplexe
US6297231B1 (en) 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1100549B1 (en) 1998-07-30 2007-03-07 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
JP2003516395A (ja) 1999-12-09 2003-05-13 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺真菌剤としてのピラゾールカルボキサミド、及びピラゾールチオアミド
JP2001187735A (ja) * 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
WO2001058428A1 (en) 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
PL205134B1 (pl) 2000-03-27 2010-03-31 Scripps Research Inst Pochodne glicylolizyny, preparat farmaceutyczny i zastosowanie pochodnych glicylolizyny
WO2001078687A1 (en) 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
WO2002102414A1 (fr) 2001-06-14 2002-12-27 Otsuka Pharmaceutical Co., Ltd. Compositions medicinales
DK1429734T3 (da) 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
JP2007509989A (ja) 2003-10-31 2007-04-19 ポイント バイオメディカル コーポレイション 超音波造影剤として有用な再構成可能なミクロスフィア組成物

Also Published As

Publication number Publication date
BRPI0415531B1 (pt) 2019-07-30
NO2014027I2 (no) 2014-10-27
US20200061057A1 (en) 2020-02-27
IL175072A (en) 2015-06-30
DK1675573T3 (da) 2009-01-05
US8030313B2 (en) 2011-10-04
TWI383810B (zh) 2013-02-01
CN1870980B (zh) 2010-06-23
CA2543242A1 (en) 2005-05-12
AR046141A1 (es) 2005-11-23
FR14C0039I1 (fr) 2014-06-27
KR100931784B1 (ko) 2009-12-14
ZA200602347B (en) 2007-09-26
TW201204413A (en) 2012-02-01
CN1870980A (zh) 2006-11-29
EP1675573B1 (en) 2008-10-22
TWI421101B (zh) 2014-01-01
AU2004285448A1 (en) 2005-05-12
DE602004017342D1 (de) 2008-12-04
US7807680B2 (en) 2010-10-05
US9763935B2 (en) 2017-09-19
PE20050811A1 (es) 2005-09-25
SI1675573T1 (sl) 2009-02-28
ECSP12006512A (es) 2012-02-29
RU2006109111A (ru) 2007-09-27
NZ546063A (en) 2009-05-31
IL175072A0 (en) 2006-08-20
LU92427I9 (pl) 2019-01-17
WO2005041937A3 (en) 2006-04-06
BRPI0415531B8 (pt) 2021-05-25
US20240261280A1 (en) 2024-08-08
CO5690539A2 (es) 2006-10-31
WO2005041937A2 (en) 2005-05-12
LU92427I2 (fr) 2014-06-11
ECSP066512A (es) 2006-10-10
CY1109040T1 (el) 2014-07-02
NO20062319L (no) 2006-07-21
DK1675573T4 (da) 2012-08-06
AR106449A2 (es) 2018-01-17
NO334919B1 (no) 2014-07-14
MXPA06004489A (es) 2006-06-20
NO2014027I1 (no) 2014-11-10
JP4836797B2 (ja) 2011-12-14
EP1675573B2 (en) 2012-06-13
ES2315721T3 (es) 2009-04-01
US20210338663A1 (en) 2021-11-04
US8952013B2 (en) 2015-02-10
MY146093A (en) 2012-06-29
JP5372032B2 (ja) 2013-12-18
AU2004285448C1 (en) 2021-08-19
US20080107745A1 (en) 2008-05-08
CY2014021I2 (el) 2017-03-15
CY2014021I1 (el) 2014-07-02
HK1095266A1 (zh) 2007-05-04
JP2011102316A (ja) 2011-05-26
AU2004285448B2 (en) 2009-06-11
CA2543242C (en) 2015-04-14
ES2315721T9 (es) 2015-11-05
PL1675573T5 (pl) 2012-10-31
US20050148597A1 (en) 2005-07-07
US8722679B2 (en) 2014-05-13
UA82561C2 (uk) 2008-04-25
US20080112986A1 (en) 2008-05-15
EP1675573A2 (en) 2006-07-05
PL1675573T4 (pl) 2016-04-29
SI1675573T2 (sl) 2012-08-31
US20080112985A1 (en) 2008-05-15
US20170348308A1 (en) 2017-12-07
TW200524638A (en) 2005-08-01
US20140018369A1 (en) 2014-01-16
GEP20115205B (en) 2011-04-26
ES2315721T5 (es) 2012-08-24
KR20060118450A (ko) 2006-11-23
ATE411797T2 (de) 2008-11-15
BRPI0415531A (pt) 2006-12-26
US20120100190A1 (en) 2012-04-26
US20080221121A1 (en) 2008-09-11
US20150024056A1 (en) 2015-01-22
JP2007509148A (ja) 2007-04-12
RU2342927C2 (ru) 2009-01-10
PT1675573E (pt) 2008-12-30

Similar Documents

Publication Publication Date Title
IL175072A0 (en) Controlled release sterile injectable aripiprazole formulation and method
ZA200501064B (en) Aripiprazole complex formulation and method
GB2406283B (en) Compliance monitor and method
SG114709A1 (en) Collagen device and method of preparing the same
EP1734866A4 (en) ULTRASONIC INTRACAVITARY MEDICAL SYSTEM AND METHOD THEREOF
EP1766596A4 (en) SYSTEM AND METHOD FOR MEDICAL SIMULATION
IL183964A0 (en) System and method for identifying and controlling ophthalmic surgical devices and components
GB0319817D0 (en) Microcapsules method for preparing same and use thereof
ZA200701398B (en) System and method for staffing temporary medical positions
GB0427930D0 (en) Implant device and method
GB2404607B (en) Apparatus and methods for tissue preparation
EP1729649A4 (en) BONE COLLECTION DEVICE AND METHOD
GB0219642D0 (en) Method and device for preparing tissues sections
EP1669051A4 (en) MEDICAL CONTAINER AND METHOD OF USE THEREOF
AU2003243663A8 (en) Vaccines for suppressing ige-mediated allergic disease and methods for using the same
IL175287A0 (en) Method for preparing drug eluting medical devices and devices obtained therefrom
PL378496A1 (pl) Sposób sterylizacji i urządzenie sterylizujące
IL179039A0 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
PT1848447E (pt) Agente de regeneração de tecido biológico e método para a preparação e utilização do mesmo
GB0416872D0 (en) System and method for medical treatment
AU2004904679A0 (en) Oral killed vaccines and method for providing same
HK1109738A (en) Oral killed vaccines and method for providing same
AU2003901252A0 (en) Device and method for treating tissue injuries
AU2003904729A0 (en) Device and method for treating tissue injuries
PL378518A1 (pl) Gwóźdź chirurgiczny i sposób wytwarzania gwoździa chirurgicznego